ETHIC is a randomized controlled trial of prophylactic enoxaparin versus standard of care in community-based COVID-19 patients

the study

 

Scale and timeline

1,370 COVID-19 patients in ~10 countries in a community setting required for this study lasting approximately 6 months

Protocol

 Participants will be randomised to receive either enoxaparin for 3 weeks or the current standard of care

Objective

To assess whether treatment with enoxaparin can reduce the thrombotic burden leading to hospital admissions/poor patient outcomes

ABOUT THE INVESTIGATOR

The Thrombosis Research Institute is a  leader in innovative solutions for the detection and treatment of thrombosis.

 

© 2020 by Thrombosis Research Institute